Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 119 (TMEM119)
- Target
- TMEM119
- Molecular classification
- Transmembrane protein, Cell surface protein (surface marker), Other
01
Overview
TMEM119 is a type-I transmembrane protein prominently and selectively expressed in microglia, the innate immune cells of the CNS, under physiological conditions. TMEM119 is widely used as a marker for microglia in human and murine tissue, facilitating distinction between CNS-resident microglia and blood-derived macrophages. Altered TMEM119 expression – typically decreased in reactive microglia during neurodegeneration and inflammation – may reflect microglial activation states. Its utility as a marker is challenged in disease where expression fluctuates or is present in peripheral tissues. TMEM119 also has non-CNS roles, promoting bone formation, mineralization, and spermatogenesis through interaction with osteogenic pathways (BMP2, ATF4). Currently, it is not known as a direct therapeutic target, but is valuable in research for monitoring microglia in neuroinflammatory and neurodegenerative diseases.
- Other names
- TMEM119TM119
02
Mechanism of action
Not applicable for drugs; TMEM119 functions primarily as a cellular marker rather than a receptor/enzyme for direct drug targeting
03
Biological functions
Distinguishing CNS-resident microglia from infiltrating monocytes/macrophagesBone formation and mineralization (promotes differentiation of myoblasts into osteoblasts via BMP2 signaling and upregulation of ATF4, according to UniProt)Spermatogenesis (mouse models)
04
Disease associations
Neurodegenerative disease (marker altered in Alzheimer’s disease, multiple sclerosis, etc.)Inflammation (including traumatic brain injury, CNS inflammation)Malignant Iris Melanoma (gene-disease association, GeneCards)Leukoencephalopathy, hereditary diffuse, with spheroids 1
05
Safety considerations
Downregulation or loss of TMEM119 in disease/injury may compromise its utility as a microglia markerTMEM119 is expressed in other cell types under certain conditions (e.g., brown adipose tissue, follicular dendritic cells), reducing specificity
06
Biomarkers
TMEM119 itself is proposed as a biomarker to distinguish microglia from infiltrating macrophages in CNS disease contextsDetection of its extracellular domain in blood/cerebrospinal fluid may provide a biomarker of reactive microglia
Beyond the preview
Go deeper on Transmembrane protein 119 (TMEM119).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane protein 119 (TMEM119).